HES1 and neoplasm: Conditional knockout of Hes1 in mouse models markedly slows tumor growth and increases the infiltration and activation of cytotoxic T lymphocytes (CTLs) in the TME (88), suggesting that targeting Hes1 may be an effective immunotherapy strategy.